Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping

Next Previous
X
Search
Trial Profile

A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Breast cancer; Ductal carcinoma; Malignant melanoma
  • Focus Pharmacodynamics; Registrational
  • Sponsors Navidea Biopharmaceuticals

    • Most Recent Events

    • 16 Jun 2016 Results of retrospective evaluation published in a Navidea Biopharmaceuticals media release.
    • 16 Jun 2016 Results of retrospective evaluation of patients from this and another phase III trial (see CT profile 700239905) were presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), according to a Navidea Biopharmaceuticals media release.
    • 25 Mar 2015 According to a Navidea Biopharmaceuticals media release, Data from this study were presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top